Overview
Charcot-Marie-Tooth disease type 4B1 (CMT4B1) is an autosomal recessive form characterized by early onset, severe peripheral neuropathy often involving demyelination and prominent sensory disturbances 1.Diagnosis
Genetic Testing: Focus on mutations in GDAP1 and PRX genes 1.
Clinical Features: Progressive distal muscle weakness and wasting, sensory abnormalities, and sensory ataxia in some cases 1.
Electrophysiological Studies: Nerve conduction studies may show demyelinating features 1.Management
Supportive Care: Physical therapy, orthotics, and assistive devices to manage muscle weakness and mobility issues 1.
Symptomatic Treatment: Address sensory disturbances and pain with appropriate analgesics as needed 1.Special Populations
Pediatrics: Early onset and severe phenotype necessitate early intervention and multidisciplinary support 1.Key Recommendations
Genetic Screening for GDAP1 and PRX Mutations in patients with early-onset AR-CMT is recommended for accurate diagnosis 1 (Evidence: Moderate).
Multidisciplinary Approach including physical therapy and orthotic support is crucial for managing motor deficits 1 (Evidence: Expert opinion).
Monitor Sensory Disturbances closely and manage symptoms with appropriate analgesics as needed 1 (Evidence: Weak).References
1 Auer-Grumbach M, Fischer C, Papić L, John E, Plecko B, Bittner RE et al.. Two novel mutations in the GDAP1 and PRX genes in early onset Charcot-Marie-Tooth syndrome. Neuropediatrics 2008. link